Cel Sci (CVM) Other Non Operating Income (2010 - 2026)
Cel Sci (CVM) posted Other Non Operating Income of -$22257.0 for Q1 2026, down 73.19% sequentially from -$12851.0 in Q4 2025.
Cel Sci (CVM) Other Non Operating Income (2010 - 2026) Analysis & Trends
Cel Sci has reported Other Non Operating Income for 17 years, with the latest figure at -$22257.0 in Q1 2026.
- Quarterly Other Non Operating Income changed N/A year-over-year to -$22257.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22058.0 (down 87.77% YoY) and the FY2025 annual result came in at $47625.0, down 73.2% from the prior year.
- Other Non Operating Income eased to -$22257.0 in Q1 2026 per CVM's latest filing, from -$12851.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $185483.0 in Q3 2024 and troughed at -$42813.0 in Q3 2023.
- A 5-year average of $17973.8 and a median of -$3771.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income soared 533.24% in 2024, then sank 186.06% in 2025.
- Over 5 years, Other Non Operating Income stood at $2195.0 in 2022, then tumbled by 2050.48% to -$42813.0 in 2023, then surged by 77.71% to -$9541.0 in 2024, then plunged by 34.69% to -$12851.0 in 2025, then sank by 73.19% to -$22257.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$22257.0, -$12851.0, and $60937.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22,257.00 |
| Dec 31, 2025 | -12,851.00 |
| Sep 30, 2025 | 60,937.00 |
| Jun 30, 2025 | -3,771.00 |
| Dec 31, 2024 | -9,541.00 |
| Sep 30, 2024 | 185,483.00 |
| Jun 30, 2024 | 4,382.00 |
| Sep 30, 2023 | -42,813.00 |
| Mar 31, 2022 | 2,195.00 |
| Dec 31, 2021 | 364,596.00 |
| Sep 30, 2021 | -2.12 Mn |
| Jun 30, 2021 | 1.12 Mn |
| Mar 31, 2021 | 3.04 Mn |
| Dec 31, 2020 | 121,606.00 |
| Sep 30, 2020 | -735,482.00 |
| Jun 30, 2020 | -950,935.00 |
| Mar 31, 2020 | 18,448.00 |
| Dec 31, 2019 | 18,448.00 |
| Sep 30, 2019 | 490,953.00 |
| Jun 30, 2019 | 1.46 Mn |